Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

Converging Cancer Neuroscience and Immuno-Oncology for a novel gene therapy against brain tumors

Obiettivo

The treatment of malignant brain tumors has seen little improvement in patient outcomes over the past twenty years due to the disease's highly treatment-resistant and heterogeneous nature. Based on an innovative concept, NEURO-GENE aims to develop a novel gene therapy for malignant brain tumors. The project proposes the groundbreaking hypothesis that a specific phospholipid induces partial cell fusion between tumor and normal brain cells, driving tumor growth, while also promoting the phagocytosis of tumor cells by macrophages, thereby fueling immunosuppression. For the first time, NEURO-GENE will integrate the fields of cancer neuroscience and immuno-oncology, building on the applicant’s previous discoveries and preliminary data. The project plans to develop an advanced therapeutic strategy using lentiviral gene delivery to inhibit this phospholipid, targeting the tumor directly while also addressing significant knowledge gaps regarding the molecular mechanisms that underlie the communication network between tumor cells and normal brain cells. NEURO-GENE will explore how this network influences tumor development, growth, and treatment resistance. The project envisions that inhibiting the phospholipid will trigger a systemic immune response by preventing the phagocytosis of dying tumor cells. This inhibition is expected to cause the release of tumor antigens into the tumor microenvironment. NEURO-GENE aims to uncover new molecular mechanisms of cell communication in the brain tumor microenvironment and to develop a gene therapy that will be delivered directly into the tumor, combining phospholipid inhibition with immune-activating strategies. If successful, this approach could offer a powerful new treatment option for one of the most challenging cancers, providing hope for improved outcomes by effectively disrupting cell communication between cancer cells and the microenvironment while also activating a systemic immune response.

Campo scientifico (EuroSciVoc)

Parole chiave

Programma(i)

Argomento(i)

Meccanismo di finanziamento

HORIZON-ERC - HORIZON ERC Grants

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) ERC-2025-ADG

Vedi tutti i progetti finanziati nell’ambito del bando

Istituzione ospitante

UNIVERSITETET I BERGEN
Contributo netto dell'UE
€ 2 480 000,00
Indirizzo
MUSEPLASSEN 1
5020 Bergen
Norvegia
Regione
Norge Vestlandet Vestland
Tipo di attività
Higher or Secondary Education Establishments
Collegamenti
Costo totale
Nessun dato

Beneficiari (2)